Journal
BRITISH JOURNAL OF CANCER
Volume 113, Issue 4, Pages 574-584Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2015.261
Keywords
LKB1; cancer; therapeutic strategies; vulnerabilities
Categories
Ask authors/readers for more resources
The LKB1 tumour suppressor is a serine/threonine kinase that functions as master regulator of cell growth, metabolism, survival and polarity. LKB1 is frequently mutated in human cancers and research spanning the last two decades have begun decoding the cellular pathways deregulated following LKB1 inactivation. This work has led to the identification of vulnerabilities present in LKB1-deficient tumour cells. Pre-clinical studies have now identified therapeutic strategies targeting this subset of tumours that promise to benefit this large patient population harbouring LKB1 mutations. Here, we review the current efforts that are underway to translate pre-clinical discovery of therapeutic strategies targeting LKB1 mutant cancers into clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available